戻る Agenda
Session 8: Innovative Designs for Acute Myeloid Leukemia: Patient, Sponsor, and Investigator Perspectives
Session Chair(s)
Robert A. Beckman, MD
Professor of Oncology and of Biostatistics, Bioinformatics, and Biomathematics
Georgetown University Medical Center, United States
The session will introduce the audience to two innovative clinical study designs for acute myeloid leukemia (AML), a highly personalized complex innovative design (Multiomic Precision Medicine) and a master protocol (BEAT AML), and culminate in a panel discussion which will use these examples to illuminate master protocols and other complex innovative designs from the perspectives of patients, trial participants, sponsors, and investigators.
Learning Objective : - Understand the concept of highly personalized complex innovative designs (CID) & master trials
- Understand how patients & trial participants view highly personalized CID & master protocols including benefits & pitfalls
- Understand how investigators work with patient communities & trial participants when designing & executing master protocols & highly personalized CID
- Understand the view of the Sponsor in a highly personalized CID or master protocol
Speaker(s)
Precision Medicine Treatment in Older AML
Amy Burd, PhD
Eilean Therapeutics, United States
Chief Scientific Officer
Multi-Omic and Functional Drug Screening Approach to Treatment Selection in AML
Pamela Becker, MD, PhD
University of California Irvine, United States
Professor of Clinical Medicine
Speaker
Uma Borate, MD
The Ohio State University, United States
Associate Professor
Speaker
Kevin Harrang
Metajure, Inc., United States
Founder & Board Member
Speaker
Jorge DiMartino, MD, PhD
Kronos Bio, United States
Chief Medical Officer
Speaker
Ken Dixon, MD
specicare, United States
Founder, Chief Medical Officer
Speaker
Crystal Reinhart, PhD
University of Illinois at Urbana-Champaign, United States
Center for Prevention Research and Development, School of Social Work